Lessons from cancer immunoediting in cutaneous melanoma
- PMID: 22924051
- PMCID: PMC3424677
- DOI: 10.1155/2012/192719
Lessons from cancer immunoediting in cutaneous melanoma
Abstract
We will revisit the dual role of the immune system in controlling and enabling tumor progression, known as cancer immunoediting. We will go through the different phases of this phenomenon, exposing the most relevant evidences obtained from experimental models and human clinical data, with special focus on Cutaneous Melanoma, an immunogenic tumor per excellence. We will describe the different immunotherapeutic strategies employed and consider current models accounting for tumor heterogeneity. And finally, we will propose a rational discussion of the progress made and the future challenges in the therapeutics of Cutaneous Melanoma, taking into consideration that tumor evolution is the resulting from a continuous feedback between tumor cells and their environment, and that different combinatorial therapeutic approaches can be implemented according to the tumor stage.
References
-
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. - PubMed
-
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. - PubMed
-
- Stutman O. Tumor development after 3 methylcholanthrene in immunologically deficient athymic nude mice. Science. 1974;183(4124):534–536. - PubMed
-
- Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology. 2002;3(11):991–998. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical